Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House
April 05 2018 - 9:00AM
Daxor Corporation
(NYSE MKT: DXR), an investment
company with medical instrumentation and biotechnology operations,
announces it will present at 3:00pm on Monday, April 9th at this
year’s MicroCap Conference and will be available for meetings with
investors on both April 9th and 10th.
Michael Feldschuh, CEO of Daxor stated, “We are looking forward
to participating in the MicroCap Conference for the first time. It
will provide us an opportunity to present Daxor’s unique technology
and significant market potential to investors.”
The MicroCap Conference is an event for investors who specialize
in small and microcap stocks. It is an opportunity to be introduced
to and speak with the management of small, innovative companies,
learn from expert panels, and meet other microcap investors
The MicroCap Conference will take place in New York City at
the Essex House on April 9th and 10th. Registration will begin on
Monday at 7:00AM and will last until the evening. Both days of the
conference will be occupied with company presentations, 1-on-1
meetings, roundtables, expert panel discussions, and
networking.
Forward-Looking Statements
Certain statements in this release may include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
regarding the impact of hiring sales staff and expansion of our
distribution channels. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risk associated with our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, FDA regulatory actions, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and additional other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. Daxor does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Contact Information:
Daxor Corporation: Soren Thompson 212-330-8502 (Investor Relations) sthompson@daxor.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024